Incidence of and survival following brain metastases among women with inflammatory breast cancer
The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC). Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (H...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2010-12, Vol.21 (12), p.2348-2355 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2355 |
|---|---|
| container_issue | 12 |
| container_start_page | 2348 |
| container_title | Annals of oncology |
| container_volume | 21 |
| creator | Dawood, S. Ueno, N.T. Valero, V. Andreopoulou, E. Hsu, L. Lara, J. Woodward, W. Buchholz, T.A. Hortobagyi, G.N. Cristofanilli, M. |
| description | The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC).
Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan–Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases.
Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19–1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43–2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months.
Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening. |
| doi_str_mv | 10.1093/annonc/mdq239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954597578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419392506</els_id><sourcerecordid>812127893</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-9dea9ba65717a4dcba591b64c8115ad9fdd4a48639792266612e6414f733b7783</originalsourceid><addsrcrecordid>eNqN0c1rFDEYBvBBFLutHr1KLuJpbL4zOUqp3daCF7XiJb6TZDQ6k7TJ7K79702ZtT0JQiCQ_Hjy8qRpXhD8hmDNjiHGFO3x5G4o04-aFRFStx3m5HGzwpqyVgnGD5rDUn5ijKWm-mlzQDFnmnG8ar6dRxucj9ajNCCIDpVN3oYtjGhI45h2IX5HfYYQ0eRnKHX5gmBK9XiXJh_RLsw_UIjDCNMEc8q3lfsKkYWamp81TwYYi3--34-aT-9OP56s28sPZ-cnby9by5WeW-086B6kUEQBd7YHoUkvue0IEeD04BwH3kmmlaZUSkmol5zwQTHWK9Wxo-b1knud083Gl9lMoVg_jhB92hSjBRdaif-QHaGEqk6zKttF2pxKyX4w1zlMkG8NweaufbO0b5b2q3-5T970k3f3-m_dFbzaAygWxiHXikJ5cEwKQpl6eDiU2f--v4f8y0jFlDDrL1_NZ_L-6oJerc1F9Wrxvja8DT6bYsPdp7qQvZ2NS-EfI_8Bb5ezBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>812127893</pqid></control><display><type>article</type><title>Incidence of and survival following brain metastases among women with inflammatory breast cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Dawood, S. ; Ueno, N.T. ; Valero, V. ; Andreopoulou, E. ; Hsu, L. ; Lara, J. ; Woodward, W. ; Buchholz, T.A. ; Hortobagyi, G.N. ; Cristofanilli, M.</creator><creatorcontrib>Dawood, S. ; Ueno, N.T. ; Valero, V. ; Andreopoulou, E. ; Hsu, L. ; Lara, J. ; Woodward, W. ; Buchholz, T.A. ; Hortobagyi, G.N. ; Cristofanilli, M.</creatorcontrib><description>The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC).
Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan–Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases.
Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19–1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43–2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months.
Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdq239</identifier><identifier>PMID: 20439340</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Biological and medical sciences ; brain metastases ; Brain Neoplasms - epidemiology ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; breast tumor subtypes ; Carcinoma - epidemiology ; Carcinoma - mortality ; Carcinoma - pathology ; Female ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Humans ; Incidence ; inflammatory breast cancer ; Inflammatory Breast Neoplasms - epidemiology ; Inflammatory Breast Neoplasms - mortality ; Inflammatory Breast Neoplasms - pathology ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Neurology ; Pharmacology. Drug treatments ; risk ; survival ; Survival Analysis ; Tumors ; Tumors of the nervous system. Phacomatoses ; Young Adult</subject><ispartof>Annals of oncology, 2010-12, Vol.21 (12), p.2348-2355</ispartof><rights>2010 European Society for Medical Oncology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-9dea9ba65717a4dcba591b64c8115ad9fdd4a48639792266612e6414f733b7783</citedby><cites>FETCH-LOGICAL-c479t-9dea9ba65717a4dcba591b64c8115ad9fdd4a48639792266612e6414f733b7783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23651237$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20439340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dawood, S.</creatorcontrib><creatorcontrib>Ueno, N.T.</creatorcontrib><creatorcontrib>Valero, V.</creatorcontrib><creatorcontrib>Andreopoulou, E.</creatorcontrib><creatorcontrib>Hsu, L.</creatorcontrib><creatorcontrib>Lara, J.</creatorcontrib><creatorcontrib>Woodward, W.</creatorcontrib><creatorcontrib>Buchholz, T.A.</creatorcontrib><creatorcontrib>Hortobagyi, G.N.</creatorcontrib><creatorcontrib>Cristofanilli, M.</creatorcontrib><title>Incidence of and survival following brain metastases among women with inflammatory breast cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC).
Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan–Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases.
Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19–1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43–2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months.
Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>brain metastases</subject><subject>Brain Neoplasms - epidemiology</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>breast tumor subtypes</subject><subject>Carcinoma - epidemiology</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Incidence</subject><subject>inflammatory breast cancer</subject><subject>Inflammatory Breast Neoplasms - epidemiology</subject><subject>Inflammatory Breast Neoplasms - mortality</subject><subject>Inflammatory Breast Neoplasms - pathology</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>risk</subject><subject>survival</subject><subject>Survival Analysis</subject><subject>Tumors</subject><subject>Tumors of the nervous system. Phacomatoses</subject><subject>Young Adult</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0c1rFDEYBvBBFLutHr1KLuJpbL4zOUqp3daCF7XiJb6TZDQ6k7TJ7K79702ZtT0JQiCQ_Hjy8qRpXhD8hmDNjiHGFO3x5G4o04-aFRFStx3m5HGzwpqyVgnGD5rDUn5ijKWm-mlzQDFnmnG8ar6dRxucj9ajNCCIDpVN3oYtjGhI45h2IX5HfYYQ0eRnKHX5gmBK9XiXJh_RLsw_UIjDCNMEc8q3lfsKkYWamp81TwYYi3--34-aT-9OP56s28sPZ-cnby9by5WeW-086B6kUEQBd7YHoUkvue0IEeD04BwH3kmmlaZUSkmol5zwQTHWK9Wxo-b1knud083Gl9lMoVg_jhB92hSjBRdaif-QHaGEqk6zKttF2pxKyX4w1zlMkG8NweaufbO0b5b2q3-5T970k3f3-m_dFbzaAygWxiHXikJ5cEwKQpl6eDiU2f--v4f8y0jFlDDrL1_NZ_L-6oJerc1F9Wrxvja8DT6bYsPdp7qQvZ2NS-EfI_8Bb5ezBg</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Dawood, S.</creator><creator>Ueno, N.T.</creator><creator>Valero, V.</creator><creator>Andreopoulou, E.</creator><creator>Hsu, L.</creator><creator>Lara, J.</creator><creator>Woodward, W.</creator><creator>Buchholz, T.A.</creator><creator>Hortobagyi, G.N.</creator><creator>Cristofanilli, M.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20101201</creationdate><title>Incidence of and survival following brain metastases among women with inflammatory breast cancer</title><author>Dawood, S. ; Ueno, N.T. ; Valero, V. ; Andreopoulou, E. ; Hsu, L. ; Lara, J. ; Woodward, W. ; Buchholz, T.A. ; Hortobagyi, G.N. ; Cristofanilli, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-9dea9ba65717a4dcba591b64c8115ad9fdd4a48639792266612e6414f733b7783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>brain metastases</topic><topic>Brain Neoplasms - epidemiology</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>breast tumor subtypes</topic><topic>Carcinoma - epidemiology</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Incidence</topic><topic>inflammatory breast cancer</topic><topic>Inflammatory Breast Neoplasms - epidemiology</topic><topic>Inflammatory Breast Neoplasms - mortality</topic><topic>Inflammatory Breast Neoplasms - pathology</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>risk</topic><topic>survival</topic><topic>Survival Analysis</topic><topic>Tumors</topic><topic>Tumors of the nervous system. Phacomatoses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dawood, S.</creatorcontrib><creatorcontrib>Ueno, N.T.</creatorcontrib><creatorcontrib>Valero, V.</creatorcontrib><creatorcontrib>Andreopoulou, E.</creatorcontrib><creatorcontrib>Hsu, L.</creatorcontrib><creatorcontrib>Lara, J.</creatorcontrib><creatorcontrib>Woodward, W.</creatorcontrib><creatorcontrib>Buchholz, T.A.</creatorcontrib><creatorcontrib>Hortobagyi, G.N.</creatorcontrib><creatorcontrib>Cristofanilli, M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dawood, S.</au><au>Ueno, N.T.</au><au>Valero, V.</au><au>Andreopoulou, E.</au><au>Hsu, L.</au><au>Lara, J.</au><au>Woodward, W.</au><au>Buchholz, T.A.</au><au>Hortobagyi, G.N.</au><au>Cristofanilli, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of and survival following brain metastases among women with inflammatory breast cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>21</volume><issue>12</issue><spage>2348</spage><epage>2355</epage><pages>2348-2355</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC).
Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified. Cumulative incidence of brain metastases was computed. Survival estimates were computed using the Kaplan–Meier product limit method. Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases.
Median follow-up was 20 months. Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively. Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively. Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19–1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43–2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant. Median survival following a diagnosis of brain metastases was 6 months.
Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>20439340</pmid><doi>10.1093/annonc/mdq239</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2010-12, Vol.21 (12), p.2348-2355 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_954597578 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences brain metastases Brain Neoplasms - epidemiology Brain Neoplasms - mortality Brain Neoplasms - secondary breast tumor subtypes Carcinoma - epidemiology Carcinoma - mortality Carcinoma - pathology Female Follow-Up Studies Gynecology. Andrology. Obstetrics Humans Incidence inflammatory breast cancer Inflammatory Breast Neoplasms - epidemiology Inflammatory Breast Neoplasms - mortality Inflammatory Breast Neoplasms - pathology Mammary gland diseases Medical sciences Middle Aged Neoplasm Metastasis Neurology Pharmacology. Drug treatments risk survival Survival Analysis Tumors Tumors of the nervous system. Phacomatoses Young Adult |
| title | Incidence of and survival following brain metastases among women with inflammatory breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T21%3A45%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20and%20survival%20following%20brain%20metastases%20among%20women%20with%20inflammatory%20breast%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Dawood,%20S.&rft.date=2010-12-01&rft.volume=21&rft.issue=12&rft.spage=2348&rft.epage=2355&rft.pages=2348-2355&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdq239&rft_dat=%3Cproquest_cross%3E812127893%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=812127893&rft_id=info:pmid/20439340&rft_els_id=S0923753419392506&rfr_iscdi=true |